Landos Biopharma Inc LABP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
22.35quote price arrow up+0.05 (+0.22%)
Volume
5,701
52 week range
2.50 - 22.84
Loading...
  • Open22.40
  • Day High22.46
  • Day Low22.29
  • Prev Close22.30
  • 52 Week High22.84
  • 52 Week High Date04/25/24
  • 52 Week Low2.50
  • 52 Week Low Date06/01/23

Key Stats

  • Market Cap69.863M
  • Shares Out3.13M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change509.29

KEY STATS

  • Open22.40
  • Day High22.46
  • Day Low22.29
  • Prev Close22.30
  • 52 Week High22.84
  • 52 Week High Date04/25/24
  • 52 Week Low2.50
  • 52 Week Low Date06/01/23
  • Market Cap69.863M
  • Shares Out3.13M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change509.29

RATIOS/PROFITABILITY

  • EPS (TTM)-3.99
  • P/E (TTM)-5.59
  • Fwd P/E (NTM)-7.20
  • EBITDA (TTM)-25.543M
  • ROE (TTM)-70.67%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-241.49%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Landos Biopharma Inc

 

Profile

MORE
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of novel, oral, once-daily therapeutics for patients with autoimmune diseases. It is engaged in the development of therapeutics that target novel pathways at the interface of immunity and metabolism. Its lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist. It is developing NX-13 as a once-daily, oral treatment for ulcerative colitis (UC), and Crohn's...
Christopher Garabedian
Independent Chairman of the Board
Gregory Oakes
President, Chief Executive Officer, Principal Financial Officer, Director
Fabio Cataldi M.D.
Executive Vice President, Chief Medical Officer
Address
1800 Kraft Drive, Suite 216
Blacksburg, VA
24060
United States